Rubicon Research Limited announced its Q4 FY26 financial results, reporting a significant year-on-year revenue growth of 44%, reaching ₹5,139 million (513.9 crore). The company also saw a substantial 112% increase in Profit After Tax (PAT), which stood at ₹768 million (76.8 crore). For the full fiscal year FY26, revenue grew by 37% to ₹17,540 million (1754 crore), and PAT increased by 84% to ₹2,467 million (246.7 crore). The company's operating EBITDA for the quarter was ₹1,190 million (119 crore), a 64% increase year-on-year, and for the full year, it grew by 52% to ₹4,000 million (400 crore). During the quarter, Rubicon Research received 12 product approvals in FY26 and has 24 products currently under FDA review. The company announced a recommended dividend of 150%, amounting to ₹1.5 per share. In a strategic move, Rubicon Research acquired an 85% stake in Arinna Lifesciences for ₹200 crore (enterprise value) to strengthen its presence in the Indian CNS market. The company also expects its Pithampur facility to ramp up within 12-18 months post-FDA inspection, aiming for decent capacity utilization. The company's R&D spend for Q4 FY26 was 11.6% of operating revenues, with an updated R&D productivity multiple of 5.9x for FY26 over FY23. Rubicon Research has guided an R&D spend of ₹500 crore over nine quarters (FY26, FY27, and Q1 FY28). The board has also approved a proposal to create an ESOP pool, subject to shareholder approval.
